Chapter 88: Drugs for Cancer Pain

Welcome to Last Minute Lecture.

This free chapter overview is designed to help students review and understand key concepts.

These summaries supplement, not replace, the original textbook and may not be redistributed or resold.

For complete coverage, always consult the official text.

90%.

Yeah.

That is how much cancer pain can be effectively relieved with just simple existing interventions.

It's a staggering number.

It really is.

Yeah.

Yet, across the country right this minute, patients are suffering needlessly.

So welcome to this deep dive.

This is specifically tailored for you, our advanced practice nursing and physician assistant students.

Today, we are delivering a Last Minute Lecture tutoring session, and we're focusing exclusively on mastering the clinical management of cancer pain.

Right.

And I think we need to start by understanding why that massive 90 % success rate isn't actually happening in reality.

What's going wrong?

Well, the disconnect is profoundly frustrating.

And it really sets the stage for the environment that you will be working in as clinicians.

When we look at the recognized barriers to pain management, the failure almost never stems from the pharmacology itself.

Right, like we have the drugs.

Exactly.

We have the necessary drugs.

The failure is systemic.

And it's highly psychological.

You are stepping into a health care system that traditionally hyper focuses on eradicating the disease.

Trinking the tumor, getting clear margins.

Yeah, exactly.

But while doing that, it inadvertently treats the relief of human suffering as just like a secondary concern.

And on top of that, there are these massive, completely unfounded fears surrounding addiction.

Oh, sure.

And those fears aren't just held by the patients.

They're shared by their families, and unfortunately, all too often by the prescribing clinicians themselves.

Wow.

Yeah, and the stakes here really could not be higher.

We have to separate the concept of pain from just mere discomfort.

Because unrelieved pain fundamentally destroys a patient's functional baseline.

Yeah.

It causes severe psychological distress.

It places this crushing burden on the family unit trying to care for them.

And chronic severe pain can actually compromise the immune system to the point where it hastens death from the cancer itself.

Right, so our goal for you today is to build a rock -solid, rational, clinical decision -making framework to prevent that specific suffering.

But to treat the pain, we first have to understand the specific pathophysiological mechanisms driving it.

Right, because you really cannot safely intervene without a comprehensive evaluation of the source.

Pathophysiologically, cancer pain typically originates from two distinct categories.

The first is from the cancer itself.

So this involves the primary tumor causing direct invasion into surrounding nerves, or muscles, or visceral organs.

Or it comes from distant metastases.

And bone metastases is a huge part of that, right?

Huge.

It is vital to anticipate that up to 50 % of cancer patients will experience severe pain from bone metastases.

Oh, wow, half of them.

Yeah, because those tumors physically stretch the periosteum and cause these microscopic fractures.

But the second major category of pain, and the one clinicians often fail to properly validate, is the pain caused by our own therapeutic interventions.

OK, let's unpack this.

Because the treatments we use to prolong the patient's life are actively causing a massive portion of their daily agony.

Are we talking about, like, just temporary soreness from a needle stick or a biopsy?

Oh, no, far from it.

We are dealing with severe dose -limiting toxicity.

Chemo, for example, targets rapidly dividing cells, which means it violently attacks the mucosal lining of the GI tract, causing agonizing mucositis.

That sounds awful.

It is.

It also damages peripheral nerves, leading to diffuse burning neuropathies.

And it can even trigger aseptic necrosis of the joints.

So the joints literally just start dying.

Exactly.

And radiation therapy carries its own unique pain profile.

It causes osteonecrosis, chronic visceral pain, and peripheral neuropathy, because the radiation actively causes fibrosis, which is heavy scarring of the nerve tissue itself.

And I imagine surgery plays a role, too.

Right, surgery, while curative and intent, leaves patients dealing with incisional pain, severed nerves, and phenomena like phantom limb syndrome.

So managing a clinical picture that complex requires a continuous feedback loop.

In practice, this is never just a one -and -done prescription.

Never.

The clinical workflow is this endless cycle.

You perform a comprehensive assessment.

You execute an intervention, starting with analgesic drugs.

Then you reassess the patient's response.

And you adjust the dosages or layer in non -drug therapies.

That's the exact loop.

But let's pause at that very first step, the assessment.

Because a common trap for new clinicians is walking into the exam room and simply asking the patient,

hey, how do you feel?

Yeah, and that approach is a profound disservice to the patient, how do you feel?

Yields a vague narrative, you know?

Not actionable clinical data.

A proper assessment demands a structured patient self -report.

You must ask highly specific questions about the onset, the character, the intensity on a validated scale, and the exacerbating factors of the pain.

Then you transition right into a rigorous physical and neurologic exam.

And the physiological reason for this is referred pain, right?

Exactly.

A patient might complain bitterly of pain radiating down their leg or in their hip.

If you just prescribe a painkiller for the hip, you've missed the fact that a tumor is actively compressing the lumbar spine.

Well,

yeah, so you take those physical findings and correlate them with diagnostic tests, like imaging or tumor markers, to definitively prove that the underlying pathology actually matches the pain they're reporting.

Right.

But there is another layer to this assessment that is arguably just as critical as the physical exam, and that is the psychosocial evaluation.

Without a psychosocial evaluation, even the most pharmacologically perfect prescription will fail.

You have to evaluate the patient's psychological state, like how have they coped with severe stress in the past?

What are their deeply held cultural or personal fears regarding opioid use?

Do they actually have a family support system capable of helping them manage a really complex around -the -clock dosing schedule?

Exactly.

If the patient is too terrified of the medication to actually swallow the pill, the intervention is useless.

So if the assessment is complete, the pathology is identified, and the psychosocial barriers are understood, the immediate question for the clinician is, well, what do I reach for first?

Yeah.

And the foundational framework for this decision has historically been the World Health Organization's analgesic ladder.

The traditional WHO ladder relies on a progressive step -up approach dictated by pain intensity.

Step one is designed for mild to moderate pain, relying strictly on non -opioid analgesics like NSAIDs and acetaminophen.

And then you move up if needed.

Exactly.

If the pain escalates and breaks through that intervention, you move to step two, which adds an opioid of moderate strength, such as oxycodone.

Finally, step three addresses severe pain by substituting those moderate opioids with highly potent pure agonists, like morphine or fentanyl.

So it dictates a steady progressive climb.

But here's where it gets really interesting, because the National Comprehensive Cancer Network, the NCCN, offers a vital pivot from that traditional ladder.

They do.

If the WHO ladder forces a patient to climb the stairs one by one, the NCCN guidelines essentially install an elevator.

That's a great way to put it.

The clinical reasoning here is that if a patient presents to you with pain that is already severe, say, like an 8 out of 10 on the pain scale, there is zero physiological benefit to forcing them to try a non -opioid first, just to check a box.

Right, you're just prolonging their suffering.

Exactly, you put them in the elevator, take them straight to the top opioid floors, and stop the suffering immediately.

And the NCCN approach is highly patient -centered for that reason.

It prioritizes immediate aggressive relief over a rigid adherence to stepping stones.

However,

this doesn't render step one drugs obsolete.

Oh, no.

Non -opioids remain foundational.

They're used either as monotherapy for mild pain, or they are combined with powerful opioids later on to attack the pain from multiple physiological angles.

But prescribing non -opioids safely in an oncology setting requires a deep understanding of their pharmacodynamics, beginning with the ceiling effect.

Right, the ceiling effect is such a critical safety concept.

Unlike opioids, where a clinician can continually titrate the dose upward to match escalating pain, non -opioids have a strict pharmacological ceiling.

They max out.

Exactly, once the patient hits a certain dosage threshold,

the enzymes, the drug targets are fully saturated.

Giving them another dose of ibuprofen will not provide a single drop of additional pain relief.

It will only push them into catastrophic organ toxicity.

Right, and the mechanism behind that toxicity is tied directly to how NSAIDs function.

Drugs like ibuprofen or aspirin relief pain and inflammation by inhibiting cyclooxygenase, specifically the Keox -1 and COX -2 enzymes, out in the peripheral tissues.

Which dials down the pain.

It does dial down the inflammatory pain response, but inhibiting those enzymes carries a steep systemic cost.

It strips the stomach of its protective mucosal lining, promoting gastric ulceration.

It restricts blood flow to the kidneys, triggering acute renal failure.

And most critically for the oncology patient, COX inhibition prevents platelet aggregation.

Wait, hold on, this is a massive clinical safe dealer.

Aren't many cancer patients on bone marrow suppressing chemo?

They are, and that bone marrow suppression leads to thrombocytopenia, meaning the patient's platelet count drops to dangerously low levels.

So they already can't clot well.

Right, so if you introduce a conventional NSAID to a thrombocytopenic patient, you are chemically destroying the clotting function of the very few platelets they have managed to produce.

That's terrifying.

Aspirin is particularly disastrous in this scenario.

Aspirin causes an irreversible inhibition of cyclooxygenase.

Irreversible.

Irreversible, that means the platelet is poisoned for its entire lifespan, which is roughly eight days.

For these vulnerable patients, conventional NSAIDs are largely contraindicated.

Clinicians must rely on nonacetylated salicylates or highly selective COX2 inhibitors, which don't disrupt platelet function though.

You do have to monitor COX2 inhibitors for increased risks of thrombotic events.

So if NSAIDs are fraught with bleeding risks, clinicians often pivot to acetaminophen.

Right.

It provides analgesia, but its mechanism of action is fundamentally different, which changes its safety profile.

Yes, acetaminophen bypasses the periphery entirely.

It exerts its AOX inhibition almost exclusively within the central nervous system.

Because it doesn't affect peripheral cyclooxygenase, it offers absolutely no anti -inflammatory benefits.

But it's safer for bleeding.

That's the massive clinical advantage.

It does not disrupt platelet aggregation and it does not cause gastric ulcers.

This makes it a vastly superior and safer option for your chemotherapy patient dealing with thrombocytopenia.

But acetaminophen has its own severe dangers that require strict monitoring.

Like it is heavily metabolized by the liver.

If a patient combines acetaminophen with even moderate amounts of alcohol, the metabolic pathways shift,

creating a highly toxic metabolite that causes fatal, irreversible liver damage.

Exactly.

Furthermore, acetaminophen interacts aggressively with warfarin by inhibiting warfarin's metabolism.

If the warfarin isn't breaking down, it just accumulates in the bloodstream to toxic levels, which dangerously increases the patient's bleeding risk.

You have to monitor their INR constantly if they are on both.

And those limitations are exactly why non -asartar periods can only take us so far.

When the cancer pain is moderate to severe or when the non -asartar periods hit their analgesic ceiling, the clinician must transition to opioids.

These are the heavy hitters.

The most potent pharmacological tools available.

And to deploy them safely, you have to understand exactly what they're doing at the receptor level.

Opioids relieve pain by mimicking the actions of the body's own endogenous opioid peptides.

They bind primarily to the mu and kappa receptors in the central nervous system.

But there is a very strict clinical rule here from the text.

When treating cancer pain, you must only prescribe pure agonist drugs like morphine, oxycodone, or fentanyl.

You must completely avoid a class of drugs known as agonist antagonists, such as buprenorphine or pentazocine.

Yeah, and the rationale for avoiding agonist antagonists comes down to receptor affinity and intrinsic activity.

Let's look at the pharmacodynamics.

Agonist antagonists bind to the kappa receptors as weak agonists, providing a mild degree of pain relief.

But crucially, they bind to the mu receptors as antagonists.

Okay, let's visualize that mechanism.

Imagine the mu receptor is a lock on a door, and a pure agonist like morphine is a key that fits perfectly, turns the lock, and opens the door to massive pain relief.

I love this analogy.

Right, so an agonist antagonist is like a broken key.

It fits perfectly into the lock, meaning it binds tightly to the mu receptor, but it cannot turn the lock to open the door.

Even worse, because it is jammed in the keyhole, it physically blocks the pure agonist keys from getting in.

That perfectly illustrates the clinical danger.

Imagine a cancer patient who has been on morphine for weeks.

Their nervous system is physically dependent on that pure agonist stimulating the mu receptors.

If you administer an agonist antagonist, that drug will sweep in, forcefully kick the morphine off the mu receptors, and act as a blockade.

And the pain relief just stops.

It instantly stops, and the sudden absence of mu receptor stimulation plunges that fragile cancer patient into a severe, violent, and agonizing withdrawal syndrome.

It's an absolute physiological nightmare that is completely preventable.

Completely.

And agonist antagonists aren't the only opioids that require strict avoidance.

Moperidine, commonly known as Demerol, is highly problematic for chronic cancer pain.

Right, the issue with Moperidine isn't the primary drug itself, but its metabolic byproduct.

When the body breaks down Moteridine, it produces a toxic metabolite called Normoperidine.

With chronic repeated dosing, Normoperidine accumulates in the central nervous system, causing severe dysphoria, extreme agitation, and ultimately life -threatening seizures.

It simply cannot be used for long -term management.

Never.

And then methadone is another pure agonist that comes with a heavy warning label.

It provides excellent analgesia, but its pharmacokinetics are incredibly deceptive.

Very deceptive.

Methadone has a dangerously prolonged half -life.

While the pain relief might only last a few hours, the drug itself remains in the body for days.

Oh, wow.

So if a clinician titrates the dose upward too quickly, treating it like short -acting morphine, the methadone silently accumulates to lethal levels, leading to profound delayed respiratory depression.

Methadone is an exceptional tool, but it should generally be managed only by clinicians with specialized training in pain management.

Makes sense.

So once you've selected the appropriate pure agonist,

the next massive hurdle is scheduling the doses.

A major rule for persistent cancer pain is that opioids must be administered around the clock, or ATC, on a fixed, unyielding schedule.

Yes.

Relying on a PRN, or as -needed dosing schedule, is a clinical failure for continuous cancer pain.

If you force the patient to wait until the pain becomes unbearable before they can request their medication, the opioid levels in their blood have already dropped to subtherapeutic levels.

So they're just suffering while waiting for it to kick in.

Exactly.

They suffer needlessly while waiting for the new dose to take effect, and this cycle breeds immense psychological anxiety as they constantly anticipate the return of the agony.

ATC scheduling provides a steady state of medication, preventing the pain from breaking through the surface in the first place.

But the reality of cancer is dynamic.

You can have a patient on a flawless ATC schedule, their baseline pain is completely controlled, but then they undergo a dressing change, or they simply cough forcefully, and they are hit with a sudden massive spike in severe pain.

Yeah, that phenomenon is known as breakthrough pain.

It is rapid in onset, highly severe, and transient.

Your clinical protocol must account for it by incorporating a rescue medication.

Which is a short -acting opioid.

Right.

This involves prescribing a fast -acting supplemental dose.

The standard guideline dictates that the rescue dose should be calculated at roughly 10 to 20 % of the patient's total daily scheduled opioid requirement.

If the pain persists, they can repeat that rescue dose in an hour.

And the mathematics of prescribing are critical here, especially when a patient's status changes, and you need to switch them from one opioid to another, or transition them from an IV route to an oral road for discharge.

That happens all the time.

Right.

Clinicians rely on equinogeic dosing charts for this.

Let's reason through a clinical scenario.

Suppose you have a patient currently receiving 10 milligrams of IV morphine every four hours, and the goal is to send them home on oral hydromorphone.

Okay, so you start by consulting the equinogeic chart to find the equivalent values.

The data shows that 10 milligrams of parenteral morphine is equinogeic to 7 .5 milligrams of oral hydromorphone.

So they theoretically provide the exact same level of pain relief.

Right.

Now you might wonder why the oral dose isn't drastically higher, given the first pass effect through the liver.

The chart already accounts for bioavailability differences.

So mathematically, the conversion dictates a dose of 7 .5 milligrams of oral hydromorphone.

But if you just write the script for 7 .5 milligrams and send them out the door, you are ignoring a massive clinical reality, which is that cross -tolerance among opioids is incomplete.

Yes, incomplete cross -tolerance is a vital safety concept.

Simply put, just because the patient's central nervous system has developed a high tolerance to the mu receptor stimulation of morphine, it does not mean their brain is equally tolerant to the mu receptor stimulation of a structurally different drug like hydromorphone.

Because the tolerance doesn't fully transfer over, that mathematically perfect dose of 7 .5 milligrams might actually act like a massive overdose for that specific patient, right?

Exactly.

It could trigger excessive sedation or lethal respiratory depression.

The safe clinical practice is to prescribe a dose slightly lower than the equianalgesic calculation suggests and then carefully titrate the dose upward over a few days until the patient's pain is fully relieved.

Now, as powerful as pure agonist opioids are, they're not a cure -all.

They often cause dose -limiting sedation or they simply fail to fully quiet the agonizing, burning sensation of neuropathic pain.

So when the opioids need help, clinicians introduce adjuvant analgesics.

I love adjuvants.

They're fascinating because their primary indications have nothing to do with pain.

These are drugs originally developed to treat depression, seizures, or arrhythmias.

But when deployed alongside opioids, they achieve three distinct goals.

They enhance the overall pain relief, they manage concurrent symptoms that exacerbate the patient's suffering, or they actively treat the side effects caused by the opioids themselves.

Right.

But if you prescribe these without explanation, you will destroy patient trust.

Imagine a patient with stage four bone cancer looking at their discharge paperwork and asking you, why are you giving me an anti -seizure pill and a clinical antidepressant?

I have cancer pain.

I don't have a psychiatric disorder.

And that is exactly where your knowledge of mechanisms drives patient education.

You explain to the patient that tricyclic antidepressants like amitriptyline are not being used to alter their mood.

We use them because they alter the neurochemistry in the spinal cord, significantly reducing the burning, tingling sensation of neuropathic pain.

That makes total sense.

And furthermore, we intentionally dose TCAs at bedtime.

They have a strong sedative side effect, which helps the patient achieve much needed sleep while safely avoiding the risk of daytime orthostatic hypotension.

And the explanation for the anti -seizure drugs like gabapentin or carbamazepine follows a similar logic.

We aren't treating epilepsy.

No, anti -seizure drugs work by suppressing spontaneous erratic neuronal firing.

When a nerve is damaged by a tumor or by chemo, it fires randomly, sending sharp, darting electric shock pain signals.

Gabapentin effectively acts as a volume knob, turning down the static of that hyperactive misfiring nerve.

And it's often preferred over carbamazepine, right?

Yes, because carbamazepine actively suppresses the bone marrow.

If your patient is already highly immunosuppressed from chemotherapy,

adding carbamazepine compounds the risk of severe infections and bleeding.

We also utilize central nervous system stimulants like dextroamphetamine.

On the surface, giving a stimulant to an exhausted dying cancer patient seems completely counterintuitive.

It does, but it serves a highly specific dual purpose.

First, stimulants actually potentiate or enhance the analgesic effect of the opioid.

But more importantly, they directly counteract the profound opioid -induced sedation.

So they can stay awake.

Right.

By reversing the drowsiness, the stimulant allows the patient to stay awake, maintain their cognitive clarity, and actually interact with their family during the day, which massively improves their quality of life.

Glucocorticoids like dexamethasone are also a major player here.

Oh, glucocorticoids are unrivaled in their ability to rapidly reduce cerebral and spinal edema.

If a tumor is swelling and actively compressing the spinal cord or the brain tissue, administering high dose steroids reduces the inflammation, which relieves the massive pressure and preserves neurologic function.

But clinical vigilance is required with steroids.

Definitely.

They are highly effective for short -term crisis management, but long -term use leads to adrenal insufficiency, osteoporosis, and a devastatingly increased risk of infection.

Finally, we use bisphosphonates as adjuvants.

Bisphosphonates are primarily indicated to treat hypercalcemia of malignancy when bone breakdown floods the blood with calcium.

However, by actively inhibiting the osteoclasts that are destroying the bone tissue, bisphosphonates also significantly reduce the deep, relentless aching pain associated with skeletal metastases.

But there are clinical scenarios where a patient's pain is entirely refractory,

like the non -opioids hit their ceiling, the opioids are maxed out to the point of intolerable side effects, and the adjuvants just aren't enough.

When pharmacological avenues are exhausted, the clinical team must pivot to non -drug physical interventions.

Right.

This involves highly invasive specialized procedures like neurolytic nerve blocks.

The objective here is permanent destruction.

The clinician uses a neurotoxic substance, typically pure alcohol or phenol, to literally destroy the specific neurons responsible for transmitting the pain signals from the tumor site to the brain.

But the obvious fear there is precision.

Right.

If you are injecting a neurotoxin to permanently destroy nerves, how do you ensure you don't accidentally destroy a motor nerve and permanently paralyze the patient's leg or cause irreversible loss of dial control?

The safety protocol is rigorous.

The clinician never injects the neurolytic agent blindly.

First, they perform a reversible trial block using a standard short -acting local anesthetic like bupivacaine.

Yeah, so if the local anesthetic successfully numbs the pain without causing unacceptable motor loss or sensory deficits, it confirms the needle placement is exactly right.

Only then do they inject the phenol.

So it's a test run.

Exactly.

And when successful, a nerve block allows the clinical team to drastically taper down the patient's

systemic opioid doses, which relieves them of severe constipation and sedation.

But it is not without danger.

There is still a small inherent risk of permanent complications like paralysis or incontinence.

The clinical team might also utilize radiation therapy, not with the intent to cure, but strictly for palliation.

Palliative radiation aims to shrink the physical mass of the tumor to relieve tissue compression.

Clinicians can use brachytherapy, which involves implanting radioactive pellets directly into localized tumors, or they can administer intravenous radiopharmaceuticals.

And those travel systemically.

Right, these IgE agents seek out areas of high bone turnover to target widespread painful bone metastases.

But the limiting factor is always the damage inflicted on healthy surrounding tissue.

Patients suffer early inflammatory reactions like skin disquimation and late reactions, developing months later, involving severe fibrosis of peripheral nerves.

All of the advanced pharmacology and invasive procedures we've discussed today, they rely on one fundamental assumption that the patient actually consents to the treatment.

You can perfectly execute the NCCN guidelines, flawlessly calculate equine analgesic cross -tolerance, and brilliantly balance a regimen of adjuvants.

But if the patient goes home and refuses to open the pill bottle, the entire clinical strategy collapses.

So we have to address the psychological barriers we mentioned at the very beginning of this deep dive.

Patient education is not a secondary administrative task.

It is an active, vital, therapeutic intervention.

If you fail to agitate your patient on exactly how these drugs work and what to expect, you are abandoning them to suffer in isolation and fear.

So practically speaking, what does this all mean?

What is the script?

You're sitting across from a patient who is in agony, but they look at you and say, if I start taking this morphine now, it won't work later when the cancer gets worse, or I watch my neighbors struggle with addiction and I absolutely refuse to become an addict.

How do you dismantle those deeply rooted fears?

You must address those exact statements with profound empathy, backed by absolute clinical facts.

When they express the fear that the drug will stop working later, they are expressing a fear of tolerance.

Your script must be clear.

Tolerance simply means your central nervous system gets used to this specific dose.

That is perfectly normal.

When that happens, we can safely increase your dose to get the exact same level of relief.

Opioid receptors do not have a ceiling for pain relief.

Developing tolerance absolutely does not mean we will run out of options or that the drug will stop working forever.

Wow, that's powerful.

And when they bring up the fear of addiction.

You must clearly delineate the physiological reality of physical dependence from the psychological pathology of addiction.

You explain it to them directly.

Physical dependence is a normal expected biological adaptation.

Your body is getting used to the presence of the drug.

If we stop it suddenly, you would feel sick.

That will happen.

And we will manage it by tapering the drug slowly when the time comes.

But physical dependence is not addiction.

Right, because addiction is completely different.

Exactly.

Addiction is a destructive behavioral pattern.

It is a psychological craving that drives people to steal or harm themselves to get a high.

In a therapeutic cancer setting, treating documented physical pain, true psychological addiction is exceptionally rare.

You have to use your clinical authority to give them permission to treat their pain without carrying the burden of guilt.

That distinction is life -changing.

It restores the patient's agency and removes the stigma of seeking relief.

As we conclude this intensive look into the management of cancer pain, there's a fascinating pharmacological concept underpinning all of this that we want you to mull over.

We talked heavily about physical dependence and around -the -clock dosing.

Consider the phenomenon of central sensitization.

Oh, that's a brilliant point.

When severe acute pain is left unrelieved because of PRN dosing or fear of opioids, the pain signals bombard the central nervous system so aggressively that they physically remodel the neuroanatomy.

The spinal neurons become hyper -excitable, transforming a temporary pain state into a permanent chronic neuropathic pain state.

It fundamentally changes how we view analgesia.

Treating pain early and aggressively isn't just an act of compassion to make the patient comfortable today.

By blocking those signals from remodeling nervous system, effective pain management is literally preventative medicine against future irreversible suffering.

Mastering this pharmacology isn't just an academic exercise to pass your board exams.

It is the exact toolset you need to protect your patients from that suffering and to fundamentally improve the dignity of their lives.

A warm thank you from the last -minute lecture team for joining us today.

Until next time, remember that 90 % of cancer pain can be relieved as long as you have the clinical framework to make it happen.